Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7309973 | 1.00 | MMEL1 (0.58) | MMEL1MMEACE | |
| SCHEMBL7310804 | 1.00 | MMEL1 (0.58) | MMEL1MMEACE | |
| SCHEMBL7340627 | 0.95 | MMEL1 (0.53) | MMEL1MME | |
| SCHEMBL7314722 | 0.95 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7309965 | 0.95 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7314983 | 0.94 | MMEL1 (0.50) | MMEL1 | |
| SCHEMBL7318630 | 0.93 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7309952 | 0.93 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7320009 | 0.92 | MMEL1 (0.48) | MMEL1 | |
| SCHEMBL7311806 | 0.91 | MMEL1 (0.51) | MMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | claimed |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| EP-4493275-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | Memorial Sloan Kettering Cancer Center (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2023177919-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220387561-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL CCSS (CR) | 2022-12-08 | — | — | US | disclosed |
| CN-109803657-B | Pharmaceutical composition | 武汉朗来科技发展有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-110237072-B | Process for preparing pharmaceutical composition | 武汉朗来科技发展有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-110237071-B | Pharmaceutical preparation and use thereof | 武汉朗来科技发展有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-2998307-A1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | Beijing Meibeita Drug Res Co., Ltd (CN) | 2016-03-23 | — | — | EP | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | ZFX, DCLRE1B, APOBEC3C | MMEL1 560/4885MME 2127/4885ACE 4415/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | MMEL1 1136/4885MME 3401/4885ACE 3927/4885 |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | ZFX, DCLRE1B, APOBEC3C | MMEL1 560/4885MME 2127/4885ACE 4415/4885 |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CHAT, PINK1, DBH | MMEL1 2599/4885MME 3038/4885ACE 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.